Evidence mapPaperPMID 40904235Full record

ReviewAdvanced healthcare materials2026

Engineering Complexity: Advances in 3D Breast Cancer Models for Precision Oncology.

Wonwoo Jeong, Sang Jin Lee

Abstract readReview
In one paragraph

Review in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wonwoo JeongWake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157, USA.
Sang Jin LeeWake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157, USA.ORCID https://orcid.org/0000-0002-3899-1909

Funding

Clinically Applicable Orofacial Cleft Reconstruction Using Structural, Compositional Biomimetic Bone ScaffoldsR01DE031285 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$682k
Production of 3D Bioprinted Autologous Vaginal Tissue Constructs for Reconstructive ApplicationsR01HD112028 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$616k
National Institute of Child Health and Human Development 1R01HD112028NICHD NIH HHS R01 HD112028NIDCR NIH HHS 1R01DE031285NIDCR NIH HHS R01 DE031285
6 · The paper itself

Abstract

Engineered in vitro cancer models are essential tools in cancer research, offering controlled microenvironments to study tumor biology and develop personalized therapies. Breast cancer, known for its complexity and high cellular heterogeneity, poses significant challenges in treatment. To address this, patient-derived in vitro breast cancer models are being used to better predict individual drug responses and guide therapy selection. Recent bioengineering efforts have focused on replicating key features of breast cancer in vitro, such as angiogenesis, tumor cell invasion, heterogeneity, interactions with the tumor microenvironment, and metastatic behavior. Technologies including organoids, microfluidic platforms, and 3D bioprinting technologies have enabled the creation of more biologically and physiologically relevant models. Each system offers specific strengths and limitations, and choosing the right model depends on the research question and desired complexity. This review highlights the current progress in engineering in vitro breast cancer models, comparing their capabilities and discussing innovations aimed at improving their biological accuracy and clinical relevance. Ongoing challenges and future directions are also addressed, with a focus on enhancing model fidelity to native breast cancer.

Indexed as

Breast NeoplasmsModels, BiologicalPrecision MedicineAnimalsBioprintingFemaleHumansOrganoidsPrinting, Three-DimensionalTumor MicroenvironmentBreast cancercancer heterogeneityin vitro modelorganoidstumor microenvironment

Identifiers

PMID40904235
PMCPMC12790322

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.